Free Republic

Using patient data from six major U.S. cancer centers, researchers developed a risk prediction model for moderate-to-severe kidney injury after receiving the chemotherapy drug cisplatin in the largest, first generalizable study of its kind Cisplatin is a highly effective chemotherapy that has been used to treat cancer for decades, but it can cause kidney injury that can potentially lead to the discontinuation of life-saving cancer treatments. Investigators developed a comprehensive tool to predict which patients are at highest risk of moderate-to-severe kidney injury after cisplatin. They found the highest-risk patients had as much as a 20-fold higher risk of developing...

Researchers have discovered that a certain type of chemotherapy improves the immune system's ability to fight off bladder cancer, particularly when combined with immunotherapy. These findings may explain why the approach, cisplatin chemotherapy, can lead to a cure in a small subset of patients with metastatic, or advanced, bladder cancer. Researchers also believe that their findings could explain why clinical trials combining another type of chemotherapy, carboplatin-based chemo, with immunotherapy have not been successful but others that use cisplatin with immunotherapy are successful. "We have known for decades that cisplatin works better than carboplatin in bladder cancer, however, the mechanisms...

The study used the chemotherapy drug cisplatin, administered orally, to disrupt the metabolism of prostate cancer cells and bring the medication directly into treatment-resistant cells. A preclinical study offers a potential new therapy for treatment-resistant prostate cancer, offering new hope for men with the disease. The study used the chemotherapy drug cisplatin, administered orally, to disrupt the metabolism of prostate cancer cells and bring the medication directly into treatment-resistant cells. University of Miami researchers validated their targets in human prostate cancer biopsies. Then they tested the treatment in human cancer cells and a mouse model of prostate cancer, to show...

Cancer centers are contending with shortages of key chemotherapy drugs, with potentially dire consequences once the scarcity starts hitting patients. A new survey released this week by the National Comprehensive Cancer Network (NCCN) found that 93 percent of cancer centers are reporting shortages of carboplatin and 70 percent are reporting shortages of cisplatin. These two drugs are commonly used together to treat a wide variety of cancers — including breast, lung, prostate and many types of leukemias — often with the aim of curing them.

Cisplatin is a chemotherapy indicated to fight tumors in many types of cancer. However, it does have major side effects—especially kidney toxicity, that can lead to acute kidney failure. In addition, patients treated with cisplatin also often report high levels of neuropathic pain. Scientists have identified a drug that could be a game changer for patients. Istradefylline, which is already approved for Parkinson's disease, could not only reduce the harmful effects of cisplatin but also improve its anti-tumor properties. These findings will now need to be confirmed in a clinical trial. Cisplatin is a chemotherapy used to treat several types...

Dear Freepers, I am asking for prayers for my dear Dad William who is dying of colon cancer. He lost his wife (and our Mom) Toni in April 2019 after 60 years of marriage. He served as an MP in Germany during the Korean War era. My brothers and I are going to miss him terribly. Thank you.